However, TriKEs composed of one scFv against CD16, another against CD33 and a human IL-15 crosslinker promote NK cell effector functions, and also increase NK cell expansion and persistence in vivo in mouse preclinical models of AML and ovarian cancer (184, 185). This evidence concerns the gene CD33 and acute myeloid leukemia.